Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
How is AI transforming the world’s original biotech company? Genentech is an American biotechnology corporation headquartered ...
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, said on Monday the company is striving to build a portfolio of obesity ...
- FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development program in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results